AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · IEX Real-Time Price · USD
33.70
-0.75 (-2.18%)
At close: Jul 19, 2024, 4:00 PM
34.07
+0.37 (1.10%)
Pre-market: Jul 22, 2024, 7:05 AM EDT
AnaptysBio Revenue
AnaptysBio had revenue of $22.96M in the twelve months ending March 31, 2024, with 114.78% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $7.18M with 422.49% year-over-year growth. In the year 2023, AnaptysBio had annual revenue of $17.16M with 66.78% growth.
Revenue (ttm)
$22.96M
Revenue Growth
+114.78%
P/S Ratio
40.09
Revenue / Employee
$196,256
Employees
117
Market Cap
920.64M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
Dec 31, 2019 | 8.00M | 3.00M | 60.00% |
Dec 31, 2018 | 5.00M | -5.00M | -50.00% |
Dec 31, 2017 | 10.00M | -6.68M | -40.06% |
Dec 31, 2016 | 16.68M | -887.00K | -5.05% |
Dec 31, 2015 | 17.57M | 1.73M | 10.94% |
Dec 31, 2014 | 15.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pacira BioSciences | 681.75M |
HealthStream | 282.88M |
CareDx | 275.11M |
BioLife Solutions | 137.30M |
Cronos Group | 93.03M |
Bicycle Therapeutics | 41.61M |
Silence Therapeutics | 33.86M |
Viridian Therapeutics | 288.00K |
ANAB News
- 2 months ago - Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) - GlobeNewsWire
- 2 months ago - Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties - GlobeNewsWire
- 3 months ago - Actym Therapeutics Appoints Thomas Smart as CEO - PRNewsWire
- 4 months ago - Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting - GlobeNewsWire
- 6 months ago - Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference - GlobeNewsWire
- 8 months ago - Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals - GlobeNewsWire